Market News (Page 1) - TendieTensor

Market News Page 1 of 292 • 7,296 articles

BuildingReports and LIV Announce Integration Partnership to Simplify Fire Compliance Reporting

GlobeNewswire Inc. • Unknown

BuildingReports and LIV Announce Integration Partnership to Simplify Fire Compliance Reporting

01/14/2026 02:00 PM • BuildingReports and LIV announced a new integration partnership that allows inspection data to flow directly from BuildingReports into LIV's compliance platform. The integration eliminates manual reporting steps, reduces administrative burden for service companies, and provides AHJs and facility managers with seamless access to inspection reports at no additional cost to BuildingReports members.

BSX - Received expanded FDA indication for WaveWriter SCS Systems, demonstrated strong clinical trial results
CHYL - The partnership enhances LIV's compliance platform by connecting it with a major inspection data provider, improving data flow and user experience for its AHJ customers. This integration strengthens its competitive position in the fire safety compliance market.

#fire safety #inspection reporting #compliance software #integration partnership #AHJ #ITM compliance #automation

JBDI Holdings Announces Receipt of Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

GlobeNewswire Inc. • Jbdi Holdings Limited

JBDI Holdings Announces Receipt of Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

01/14/2026 01:52 PM • JBDI Holdings Limited (Nasdaq: JBDI) announced it received a delisting notice from Nasdaq on January 7, 2026, due to failure to maintain the minimum bid price of $1.00 over 30 consecutive business days. The company has 180 calendar days until July 6, 2026, to regain compliance. If unsuccessful, it may be eligible for an additional 180-day compliance period if it meets other listing standards, or face delisting.

ABT - Introduced Proclaim Plus system with multi-area pain coverage, but less prominent in the article compared to other companies
JBDI - The company received a delisting notice from Nasdaq for failing to maintain the minimum $1.00 bid price requirement. While the company has 180 days to regain compliance and the stock remains listed, the notice indicates financial distress and regulatory non-compliance, which poses a significant risk to shareholders and the company's market standing.

#delisting notice #minimum bid price requirement #Nasdaq Capital Market #compliance period #reverse stock split #listing standards

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

GlobeNewswire Inc. • Portnoy Law Firm

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

01/14/2026 01:33 PM • Skye Bioscience investors are being advised of a class action lawsuit covering the period from November 4, 2024 to October 3, 2025. The action follows Skye's October 6, 2025 announcement that its nimacimab drug failed to achieve the primary endpoint of weight loss compared to placebo in a Phase 2a study, with lower than expected drug exposure. The stock price fell 60% to $1.90 per share on the news.

SKYE - The company's lead drug candidate failed to meet primary endpoints in clinical trials, resulting in a 60% stock price decline. The failure to achieve weight loss compared to placebo and lower than expected drug exposure indicate significant setbacks for the company's pipeline and investor value.

#class action lawsuit #Skye Bioscience #nimacimab #Phase 2a trial failure #stock price decline #securities fraud #investor losses

Winnebago Industries Showcases Bold New RV Innovations Across Premium Brands at Florida RV SuperShow

GlobeNewswire Inc. • Na

Winnebago Industries Showcases Bold New RV Innovations Across Premium Brands at Florida RV SuperShow

01/14/2026 01:31 PM • Winnebago Industries showcased its latest recreational vehicle innovations at the Florida RV SuperShow, featuring new models across its premium brands including Winnebago, Grand Design RV, and Newmar. Highlights include the debut of the Winnebago Sunflyer Class C RV, Grand Design's Foundation 42GD destination trailer, and Newmar's Freedom Aire compact luxury coach. The company emphasized its commitment to innovation, safety features, and smart connectivity across various price points.

BAYRY - Produces and packages crop protection products, directly benefiting from agricultural packaging market growth
WGO - The company is actively launching multiple new products and models across its three premium brands, demonstrating strong innovation pipeline and market expansion. The emphasis on cutting-edge features, safety, and customer-focused design indicates robust business activity and competitive positioning in the RV market.

#RV industry #product innovation #motorhomes #travel trailers #luxury coaches #outdoor lifestyle #new model launches

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

GlobeNewswire Inc. • Delveinsight

Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight

01/14/2026 01:00 PM • The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

NVS - FABHALTA (iptacopan) is positioned as a potentially first-in-class oral complement inhibitor for advanced gMG management with Phase III data expected by 2027, addressing significant unmet needs in refractory disease.

#generalized myasthenia gravis #immunotherapy #complement inhibitors #FcRn antagonists #CAR T-cell therapy #autoimmune disease #drug pipeline #clinical trials

ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

ABX Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:58 PM • The Schall Law Firm is investigating Abacus Global Management, Inc. (NYSE: ABX) for potential securities violations following a Morpheus Research report alleging the company manipulated portfolio valuation methodology and used questionable life expectancy calculation methods to inflate profitability. The firm is seeking shareholders who suffered losses to participate in the investigation.

ABX - The company is under investigation for issuing false/misleading statements, manipulating valuation methodologies to appear more profitable, using questionable life expectancy estimates, and co-founders have documented red flags. These allegations suggest serious accounting fraud and investor deception.

#securities fraud #false statements #portfolio valuation #life settlements #accounting scheme #shareholder litigation #SPAC

AVNW Investors Have Opportunity to Join Aviat Networks, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

AVNW Investors Have Opportunity to Join Aviat Networks, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:57 PM • The Schall Law Firm is investigating Aviat Networks, Inc. (NASDAQ: AVNW) for potential securities law violations, alleging the company issued false or misleading statements and failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.

IONQ.WS - High cash burn, minimal revenue, continuous stock issuances, and speculative trading without meaningful commercial applications
AVNW - The company is under investigation for alleged securities law violations, including issuing false/misleading statements and failing to disclose material information to investors, which directly harms shareholder value and investor confidence.

#securities fraud #shareholder litigation #false statements #disclosure violations #class action lawsuit

CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

CVS/Aetna Medicare Advantage Plans Policy Holders Have Opportunity to Join Investigation into Improper Claim Denial for Post-Acute Care with the Schall Law Firm

01/14/2026 12:55 PM • The Schall Law Firm is investigating CVS Health Corporation's Aetna Medicare Advantage plans for potentially wrongfully denying prior authorizations for post-acute care using artificial intelligence without proper medical professional review, as required by contracts. The investigation covers claims from November 2019 to present, and CVS's AI practices have recently drawn scrutiny from the U.S. Senate.

RGTIW - CEO selling stock, primarily in R&D phase, years away from meaningful revenue
CVS - CVS is the subject of a formal investigation by a national litigation firm for allegedly breaching contracts by using AI to deny post-acute care claims without required medical professional review. The conduct has drawn U.S. Senate scrutiny, indicating potential regulatory and legal risks.

#CVS Health #Aetna Medicare Advantage #claim denial #prior authorization #artificial intelligence #post-acute care #breach of contract #investigation

TMSNY Investors Have Opportunity to Join Temenos AG Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

TMSNY Investors Have Opportunity to Join Temenos AG Fraud Investigation with the Schall Law Firm

01/14/2026 12:55 PM • The Schall Law Firm announced an investigation into Temenos AG for potential securities law violations, focusing on whether the company issued false or misleading statements or failed to disclose material information to investors. The firm is seeking shareholders who suffered losses to participate in the investigation.

RGTI - CEO selling stock, primarily in R&D phase, years away from meaningful revenue
TMSNY - The company is under investigation for potential securities law violations, including issuing false/misleading statements and failing to disclose material information, which indicates serious compliance concerns and potential investor harm.

#securities litigation #shareholder rights #false statements #disclosure violations #class action lawsuit

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • The Schall Law Firm

BBNX Investors Have Opportunity to Join Beta Bionics, Inc. Fraud Investigation with the Schall Law Firm

01/14/2026 12:53 PM • The Schall Law Firm is investigating Beta Bionics, Inc. for potential securities law violations, alleging the company issued false or misleading statements regarding patient starts. Beta Bionics disclosed lower-than-expected patient numbers on January 8, 2026, causing its stock to plummet over 37% the following day. The firm is seeking shareholders who suffered losses to participate in the investigation.

QBTS - Overvalued stock with high price-to-sales multiple and limited commercial quantum computing applications
BBNX - The company is under investigation for potential securities fraud involving false or misleading disclosures about patient starts. The stock experienced a severe 37% decline following the announcement of lower-than-expected patient numbers, indicating significant loss of investor confidence and potential regulatory violations.

#securities fraud #shareholder litigation #Beta Bionics #stock decline #misleading statements #patient starts #class action lawsuit

JP Morgan Stock To Remain 'Range Bound' Until Clarity On Credit Card APR: Analyst

Benzinga • Lekha Gupta

JP Morgan Stock To Remain 'Range Bound' Until Clarity On Credit Card APR: Analyst

01/14/2026 12:52 PM • JPMorgan Chase reported Q4 earnings with net income of $13.0 billion ($4.63 per share, down 7% YoY) but beat adjusted EPS estimates at $5.23. The company posted strong loan growth (up 4% sequentially) and raised 2026 NII guidance to ~$103 billion. Goldman Sachs maintained a Buy rating with a $386 price target, raising 2026-2027 PPNR and EPS estimates. However, the analyst expects JPM shares to remain range-bound until there is clarity on potential credit card APR limits and the Card Competition Act.

GOOG - Diversified technology portfolio, strategic quantum computing research through DeepMind, potential for vertical integration in AI ecosystem
AMJB - Mixed signals: Strong operational results with beat on adjusted EPS, solid loan growth, and raised guidance support positive outlook. However, regulatory uncertainty around credit card APR limits and the Card Competition Act creates near-term headwinds, causing analyst to expect range-bound trading despite maintaining Buy rating. Stock down 1% on publication day.

#JPMorgan Chase #Q4 earnings #net income #EPS #loan growth #net interest income #credit card APR #Card Competition Act #Goldman Sachs #Buy rating

Why Are Bank of America Shares Trading Lower On Wednesday?

Benzinga • Lekha Gupta

Why Are Bank of America Shares Trading Lower On Wednesday?

01/14/2026 12:50 PM • Bank of America shares declined 5% on Wednesday despite beating earnings expectations with net income of $7.6 billion and EPS of 98 cents (vs. 96 cents consensus). Revenue increased 7% YoY to $28.532 billion, also beating estimates. The bank guided for 5-7% net interest income growth in 2026. Goldman Sachs maintained a Buy rating with a $64 price target, citing strong core PPNR and ROTCE performance, though analysts seek clarity on NII drivers and capital return plans.

GOOGL - Diversified technology portfolio, strategic quantum computing research through DeepMind, potential for vertical integration in AI ecosystem
BAC - Despite beating earnings and revenue estimates with strong financial metrics (net income $7.6B, EPS 98 cents, 7% revenue growth), shares traded down 5% on the day. The decline suggests market disappointment with forward guidance or concerns about sustainability of recent performance improvements, particularly regarding net interest income outlook and capital return plans.

#Bank of America #earnings #fourth-quarter results #net interest income #Goldman Sachs #stock decline #guidance

Dave Cantin Group Announces Sale of Midwestern Auto Group to Jeff Wyler Automotive Family; Ferrari and Lamborghini Among 14 Franchises in Historic $500 Million in Total Acquisition Value Transaction

GlobeNewswire Inc. • Dave Cantin Group

Dave Cantin Group Announces Sale of Midwestern Auto Group to Jeff Wyler Automotive Family; Ferrari and Lamborghini Among 14 Franchises in Historic $500 Million in Total Acquisition Value Transaction

01/14/2026 12:50 PM • Jeff Wyler Automotive Family has acquired Midwestern Auto Group in a $500 million deal covering 14 premium and luxury automotive franchises including Ferrari, Lamborghini, Rolls-Royce, and Bentley. The transaction, facilitated by Dave Cantin Group as sell-side advisor, represents one of the largest luxury automotive acquisitions in U.S. history and the largest in Ohio. The acquisition expands Wyler's portfolio to 64 total franchises across the region while keeping the business privately held and Ohio-based.

GS - Provided private wealth management services for the transaction and CEO David Solomon expressed commitment to continued partnership with Dave Cantin Group, indicating successful engagement and relationship strengthening.

#automotive acquisition #luxury dealerships #Ferrari #Lamborghini #succession planning #M&A advisory #private transaction #Ohio dealership

WLTH Investors Have Opportunity to Join Wealthfront Corporation Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. • Schall Law Firm

WLTH Investors Have Opportunity to Join Wealthfront Corporation Fraud Investigation with the Schall Law Firm

01/14/2026 12:50 PM • The Schall Law Firm is investigating Wealthfront Corporation (NASDAQ: WLTH) for potential securities law violations, alleging false or misleading statements and inadequate disclosures. The investigation was prompted by a 14% stock price drop following the company's quarterly earnings report, which revealed softening asset flows in November and December.

WLTH - The company is under investigation for potential securities violations and false disclosures. Additionally, the stock experienced a significant 14% decline following disappointing quarterly earnings with weakening asset flows, indicating deteriorating business performance and investor confidence.

#securities fraud #shareholder litigation #Wealthfront #asset flows #earnings report #class action lawsuit

iRhythm Tech's Stock Selloff Went Too Far After Preliminary Update: Analyst

Benzinga • Vandana Singh

iRhythm Tech's Stock Selloff Went Too Far After Preliminary Update: Analyst

01/14/2026 12:43 PM • iRhythm Technologies reported strong preliminary Q4 2025 results with full-year revenue exceeding guidance and 2026 guidance of $870-880M (17-18% YoY growth). However, the stock fell ~20% due to the delay of Zio MCT launch to 2027 and 2026 guidance missing Street expectations. William Blair analyst Brandon Vazquez believes the selloff is overblown and maintains an Outperform rating, adding the stock to their Conviction List at 7x 2026 sales valuation.

BLFS - Mentioned as a key player in the cell and gene therapy infrastructure market without specific growth or investment details
IRTC - Despite a 20% stock decline, the company delivered strong operational results with full-year 2025 revenue exceeding guidance and solid 2026 guidance of $870-880M (17-18% growth). William Blair analyst maintains Outperform rating and believes the selloff is overblown, viewing the company as well-positioned for growth with attractive valuation at 7x 2026 sales. The Zio MCT delay to 2027 is a near-term setback but does not alter the fundamental thesis.

#iRhythm Technologies #Q4 2025 earnings #revenue guidance #Zio MCT delay #stock selloff #analyst rating #digital health

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

Benzinga • Vandana Singh

Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

01/14/2026 12:36 PM • Amgen announced Phase 2 study results for MariTide, its obesity treatment, showing that participants maintained weight loss achieved in part 1 for an additional 52 weeks on lower monthly or quarterly doses. The drug demonstrated up to 20% average weight loss in people with obesity without Type 2 diabetes and up to 17% in those with the condition. The treatment was well-tolerated with low incidence of nausea and vomiting, with no new safety signals observed. Amgen currently has six Phase 3 studies underway for MariTide across obesity and related conditions.

LZAGY - Listed as a key market player without specific performance indicators in the article
AMGN - Amgen reported positive Phase 2 results for MariTide showing sustained weight loss with less frequent dosing, strong tolerability profile, and no new safety concerns. Analysts view it as a differentiated product with multibillion-dollar peak sales potential and maintain Outperform ratings. Stock showed positive momentum at time of publication.

#MariTide #obesity treatment #weight loss #Phase 2 study #Phase 3 trials #GLP-1 therapies #Type 2 diabetes #cardiometabolic parameters

Why This AI ETF's Top Holdings Could Deliver a 300% return by 2030

The Motley Fool • James Hires

Why This AI ETF's Top Holdings Could Deliver a 300% return by 2030

01/14/2026 12:36 PM • The Global X Artificial Intelligence and Technology ETF (AIQ) is positioned as a solid investment opportunity as the AI industry is projected to reach $826.7 billion by 2030. With a 3-year average annualized return of 36.4%, the ETF's top holdings—Alphabet, Samsung, and Tesla—are highlighted as key drivers of potential growth, supported by strong performance in AI-related segments including autonomous vehicles, chip manufacturing, and autonomous driving technology.

AIQ - The ETF is presented as a solid investment opportunity with strong historical returns (36.4% annualized over 3 years), exposure to high-growth AI companies, and potential for significant future gains based on industry growth projections to $826.7 billion by 2030.

#AI ETF #artificial intelligence #investment #technology stocks #autonomous vehicles #chip manufacturing #market growth

Rexel: Statement relating to the total number of shares and voting rights as of December 31, 2025

GlobeNewswire Inc. • Na

Rexel: Statement relating to the total number of shares and voting rights as of December 31, 2025

01/14/2026 12:00 PM • Rexel reported 296,096,004 shares outstanding as of December 31, 2025, with 293,205,756 exercisable voting rights. The company also announced a biannual share buyback program update and moved forward its full-year 2025 results publication from February 12, 2026 to an earlier date.

HAL - Panel participation suggests standard industry representation
RXEEY - The article contains routine corporate governance disclosures regarding share counts and voting rights, along with administrative updates to the financial calendar. No material business developments, financial performance metrics, or strategic announcements are presented that would warrant a positive or negative sentiment.

#share buyback program #voting rights #treasury shares #financial results #liquidity agreement #NATIXIS ODDO BHF

Custom Ink Reveals 2026 Corporate Swag Trends: Quality Over Quantity

GlobeNewswire Inc. • Na

Custom Ink Reveals 2026 Corporate Swag Trends: Quality Over Quantity

01/14/2026 12:00 PM • Custom Ink's 2026 Swag Trends Survey reveals a significant shift in corporate promotional merchandise strategy, with 67% of buyers prioritizing longevity and quality over volume. Key trends include heavyweight fabrics (62%), garment-dyed colors (50%), and boxy cuts (46%), while wellness items and cozy gear lead non-apparel categories. Made in USA products and sustainability are increasingly important, with 61% rating American-made items as very or extremely important. Standard cotton t-shirts and basic plastic bottles are losing favor as organizations invest in meaningful swag to build team unity and company culture.

ARXCY - Participating in panel discussion indicates standard industry engagement
NKE - Nike is specifically mentioned as a recognized retail brand that corporate buyers prefer for promotional merchandise, with 91% of buyers believing teams feel more valued receiving recognized brands like Nike compared to generic alternatives.

#promotional merchandise #corporate swag #quality over quantity #team unity #sustainability #Made in USA #wellness gear #heavyweight apparel #garment-dyed colors #company culture

Rexel : Déclaration relative au nombre total d'actions et de droits de vote au 31 décembre 2025

GlobeNewswire Inc. • Na

Rexel : Déclaration relative au nombre total d'actions et de droits de vote au 31 décembre 2025

01/14/2026 12:00 PM • Rexel reported 296,096,004 total shares and voting rights as of December 31, 2025. The company updated its liquidity agreement with NATIXIS ODDO BHF and moved forward the publication of its full-year 2025 results from February 12, 2026 to an earlier date.

RXEEY - The article reports routine corporate governance matters including share count disclosure and a liquidity agreement update. The advancement of results publication could be viewed positively, but the overall tone is factual and administrative without significant positive or negative developments.

#share buyback #voting rights #liquidity agreement #financial results #2025

Bronstein, Gewirtz & Grossman LLC Urges Fermi Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Fermi Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/14/2026 12:00 PM • A class action lawsuit has been filed against Fermi Inc. (NASDAQ: FRMI) alleging that the company made materially false and misleading statements regarding its Project Matador campus, including overstating tenant demand and concealing reliance on a single tenant's funding commitment. The lawsuit covers investors who purchased Fermi securities during its October 2025 IPO or between October 1 and December 11, 2025. The lead plaintiff deadline is March 6, 2026.

FRMI - The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding Project Matador's tenant demand and funding commitments, which directly harms investor confidence and shareholder value.

#class action lawsuit #securities fraud #Fermi Inc. #Project Matador #IPO #investor harm #misleading statements #tenant funding

Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/14/2026 12:00 PM • A class action lawsuit has been filed against Ardent Health, Inc. alleging that the company made materially false and misleading statements regarding its Q3 2025 revenue and 2025 EBITDA guidance. The complaint claims revenue was overstated due to inadequate accounts receivable assessments following a new accounting system transition, and EBITDA guidance was overstated by approximately $57.5 million (9.6%) due to industry-wide cost pressures and payer denials. Investors who purchased Ardent securities between July 18, 2024 and November 12, 2025 are encouraged to join the lawsuit, with a lead plaintiff deadline of March 9, 2026.

ARDT - The company is accused of making materially false and misleading statements about its financial performance, specifically overstating Q3 2025 revenue and 2025 EBITDA guidance by approximately $57.5 million. These allegations of securities fraud and inadequate financial disclosures represent significant legal and reputational risks to the company.

#class action lawsuit #securities fraud #revenue overstatement #EBITDA guidance #accounts receivable #investor harm #federal securities laws

Bronstein, Gewirtz & Grossman LLC Urges F5, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges F5, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/14/2026 12:00 PM • A class action lawsuit has been filed against F5, Inc. alleging that the company made materially false and misleading statements about its security capabilities while concealing a significant security breach affecting key products. Investors who purchased F5 securities between October 28, 2024 and October 27, 2025 are encouraged to join the case, with a lead plaintiff deadline of February 17, 2026.

FFIV - The company is accused of making materially false and misleading statements about its security capabilities while concealing a significant security breach. Investors allegedly purchased securities at artificially inflated prices based on false information, resulting in investor harm and a class action lawsuit.

#class action lawsuit #securities fraud #F5 Inc. #security breach #investor harm #materially false statements #artificially inflated prices

Bronstein, Gewirtz & Grossman LLC Urges Smartsheet Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Smartsheet Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/14/2026 12:00 PM • A class action lawsuit has been filed against Smartsheet Inc. and its executives alleging securities fraud in connection with the January 2025 acquisition by a consortium including Blackstone, Vista Equity Partners, and the Abu Dhabi Investment Authority. The complaint claims defendants made false and misleading statements in proxy filings, mischaracterized the company's financial performance, and failed to disclose material information to stockholders.

BX - Blackstone is mentioned as part of the acquisition consortium but is not named as a defendant in the lawsuit; the litigation focuses on Smartsheet's disclosures rather than the acquirer's conduct.

#class action lawsuit #securities fraud #proxy statement #merger #stockholder approval #disclosure violations #financial misrepresentation

Deadline Alert: Varonis Systems, Inc. (VRNS) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. • Glancy Prongay & Murray Llp

Deadline Alert: Varonis Systems, Inc. (VRNS) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

01/14/2026 12:00 PM • Varonis Systems faces a securities fraud class action lawsuit after missing Q3 2025 revenue estimates and reporting a 63.9% decline in term license subscription revenues. The company reduced full-year ARR guidance, citing underperformance in its on-premises subscription business and sales process issues. The stock fell 48.7% on October 29, 2025. Investors have until March 9, 2026 to file a lead plaintiff motion.

VRNS - The company missed Q3 revenue estimates, reported a significant 63.9% decline in term license subscription revenues year-over-year, reduced full-year ARR guidance, and experienced a 48.7% stock price decline. Additionally, management acknowledged sales process issues and described the on-premises subscription business as a 'drag' on growth. The securities fraud lawsuit alleges material misstatements and failure to disclose adverse business conditions.

#securities fraud #class action lawsuit #revenue miss #ARR guidance reduction #stock price decline #on-premises subscription business